跳至主要内容
临床试验/NCT01219114
NCT01219114撤回不适用

A Descriptive Study of the Efficacy and Safety of CUBICIN (Daptomycin) Under Conditions of Actual Use in the Philippines

AstraZeneca1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2010年10月最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
AstraZeneca
入组人数
200
试验地点
1
主要终点
Adverse events observed during the treatment duration

研究概览

简要总结

The purpose of this study is to monitor the safety and efficacy of CUBICIN under conditions of actual use in patients who are diagnosed with complicated Skin and Skin Structure infection (cSSI) or Staphylococcus aureus bacteria including right-sided endocarditis and are prescribed CUBICIN by their physician.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of cSSSI known or suspected to be due to gram-positive bacteria
  • Diagnosis of right-sided endocarditis with one or more positive culture for S. aureus within two days prior to initiation of medication
  • Prescribed daptomycin by patient's attending physician

排除标准

  • Known allergic or serious adverse reaction to daptomycin
  • Patients with pneumonia
  • Patients with baseline CPK values >1000 U/L or 5x ULN

结局指标

主要结局

Adverse events observed during the treatment duration

时间窗: Ranges from during treatment and up to 14 days after last administration of daptomycin (follow up)

Clinical Response determined by cure rate

时间窗: Ranges from during treatment and up to 14 days after last administration of daptomycin

次要结局

未报告次要终点

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验